share_log

Loss-making DENTSPLY SIRONA (NASDAQ:XRAY) Sheds a Further US$273m, Taking Total Shareholder Losses to 42% Over 3 Years

Loss-making DENTSPLY SIRONA (NASDAQ:XRAY) Sheds a Further US$273m, Taking Total Shareholder Losses to 42% Over 3 Years

虧損的DENTSPLY SIRONA(納斯達克股票代碼:XRAY)又下跌2.73億美元,使股東損失總額在3年內達到42%
Simply Wall St ·  2023/11/10 10:20

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But if you try your hand at stock picking, your risk returning less than the market. We regret to report that long term DENTSPLY SIRONA Inc. (NASDAQ:XRAY) shareholders have had that experience, with the share price dropping 44% in three years, versus a market return of about 16%. The falls have accelerated recently, with the share price down 30% in the last three months. We note that the company has reported results fairly recently; and the market is hardly delighted. You can check out the latest numbers in our company report.

爲了證明選擇個股的努力是合理的,值得努力擊敗市場指數基金的回報。但是,如果你嘗試選股,你的風險回報將小於市場。我們遺憾地報告,DENTSPLY SIRONA Inc.(納斯達克股票代碼:XRAY)的長期股東也有這樣的經歷,股價在三年內下跌了44%,而市場回報率約爲16%。最近,跌幅加快,股價在過去三個月中下跌了30%。我們注意到,該公司最近才公佈業績;市場對此並不滿意。您可以在我們的公司報告中查看最新數字。

Since DENTSPLY SIRONA has shed US$273m from its value in the past 7 days, let's see if the longer term decline has been driven by the business' economics.

由於DENTSPLY SIRONA在過去7天內貶值了2.73億美元,讓我們看看長期下跌是否是由該公司的經濟推動的。

See our latest analysis for DENTSPLY SIRONA

查看我們對 DENTSPLY SIRONA 的最新分析

DENTSPLY SIRONA isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

DENTSPLY SIRONA目前沒有盈利,因此大多數分析師會關注收入增長,以了解基礎業務的增長速度。一般而言,沒有利潤的公司預計每年都會以不錯的速度增長收入。那是因爲可以很容易地推斷出快速的收入增長來預測利潤,而利潤通常規模相當大。

In the last three years, DENTSPLY SIRONA saw its revenue grow by 4.1% per year, compound. That's not a very high growth rate considering it doesn't make profits. Indeed, the stock dropped 13% over the last three years. If revenue growth accelerates, we might see the share price bounce. But ultimately the key will be whether the company can become profitability.

在過去的三年中,DENTSPLY SIRONA的收入每年增長4.1%。考慮到它不賺錢,這並不是一個很高的增長率。事實上,該股在過去三年中下跌了13%。如果收入增長加速,我們可能會看到股價反彈。但歸根結底,關鍵將是公司能否盈利。

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

您可以在下面看到收入和收入如何隨着時間的推移而變化(點擊圖片了解確切的值)。

earnings-and-revenue-growth
NasdaqGS:XRAY Earnings and Revenue Growth November 10th 2023
納斯達克:Xray 收益和收入增長 2023 年 11 月 10 日

We like that insiders have been buying shares in the last twelve months. Even so, future earnings will be far more important to whether current shareholders make money. If you are thinking of buying or selling DENTSPLY SIRONA stock, you should check out this free report showing analyst profit forecasts.

我們喜歡內部人士在過去十二個月中一直在購買股票。即便如此,未來的收益對於當前股東是否賺錢將更爲重要。如果您正在考慮買入或賣出DENTSPLY SIRONA股票,則應查看這份顯示分析師利潤預測的免費報告。

A Different Perspective

不同的視角

While the broader market gained around 9.8% in the last year, DENTSPLY SIRONA shareholders lost 8.6% (even including dividends). Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 4% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with DENTSPLY SIRONA , and understanding them should be part of your investment process.

儘管去年整個市場上漲了約9.8%,但DENTSPLY SIRONA的股東卻下跌了8.6%(甚至包括股息)。即使是優質股票的股價有時也會下跌,但我們希望看到企業的基本指標有所改善,然後才會變得過於感興趣。令人遺憾的是,去年的業績結束了糟糕的表現,股東們在五年內每年面臨4%的總虧損。我們意識到,羅斯柴爾德男爵曾說過,投資者應該 “在街頭流血時買入”,但我們警告說,投資者應首先確保他們購買的是高質量的企業。我發現從長遠來看,將股價視爲業務表現的代表非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。例如,以永遠存在的投資風險幽靈爲例。我們已經發現了DENTSPLY SIRONA的1個警告信號,理解這些信號應該成爲您投資過程的一部分。

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

還有很多其他公司有內部人士購買股票。你可能不想錯過這份業內人士正在收購的成長型公司的免費名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論